Blindness Clinical Trial
Official title:
Emergency Egress and Information System for Persons With Vision Loss
Verified date | January 2014 |
Source | VA Office of Research and Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
The purpose of the research project is to develop and evaluate an emergency egress system for persons with visual impairment, which would use existing lighted exit signage to provide egress information at a distance of up to 100 feet.
Status | Terminated |
Enrollment | 17 |
Est. completion date | April 2009 |
Est. primary completion date | December 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Must Be Blind with no better vision than light perception - Must be able to walk the necessary distances, i.e., three hours of intermittent indoor walking - OMCT (Orientation-Memory Concentration Test) of 10 or less Exclusion Criteria: - Patients currently being treated at Atlanta VA Medical Center |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
United States | Atlanta VA Medical and Rehab Center, Decatur | Decatur | Georgia |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to Exit Building | Subjects are walked into a building to a specific location and then asked to find their way out of the building. Time to Exit Building is measured. This is protocol is performed twice, and the times averaged to obtain the outcome measure. | 30 minutes total, 15 minutes for each of two timed trials | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02393118 -
A Study to Evaluate the BrainPort Vision Device in Individuals Blinded by Traumatic Injury
|
N/A | |
Terminated |
NCT00691444 -
Blind Child Melatonin Treatment Study
|
N/A | |
Recruiting |
NCT06237829 -
Testing Tactile Aids With Blind Subjects
|
N/A | |
Completed |
NCT00829036 -
Wayfinding Information Access System for People With Vision Loss
|
N/A | |
Completed |
NCT02643238 -
Continued Study of Artificial Vision: Evaluation of the BrainPort® System and Investigation of Visual Ambulation
|
N/A | |
Completed |
NCT01488786 -
A Study to Evaluate the BrainPort® Vision Device in Subjects Who Are Blind
|
N/A | |
Recruiting |
NCT00403143 -
Do Blue-Blocking Lenses Block Blue Colour From Our Lives?
|
N/A | |
Recruiting |
NCT06451172 -
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
|
Early Phase 1 | |
Recruiting |
NCT04725760 -
Evaluation of the Efficacy of the BrainPort Vision Pro on the Performance of Daily Activities in the Profoundly Blind French Population
|
N/A | |
Recruiting |
NCT02983370 -
Development of a Cortical Visual Neuroprosthesis for the Blind
|
N/A | |
Not yet recruiting |
NCT06070467 -
Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases
|
||
Completed |
NCT00920231 -
Computer Vision System for the Blind Veteran
|
Phase 1 | |
Completed |
NCT01109576 -
Workshops for Veterans With Vision and Hearing Loss
|
Phase 0 | |
Terminated |
NCT00795236 -
Melatonin Studies of Totally Blind Children
|
N/A | |
Terminated |
NCT00634972 -
Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity
|
Phase 4 | |
Enrolling by invitation |
NCT06364605 -
MySpace: the Role of Vision in Representing Space
|
N/A | |
Terminated |
NCT03913130 -
Extension Study to Study PQ-110-001 (NCT03140969)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05806684 -
Hyperbilirubinemia and Retinopathy of Prematurity in Preterm Infants: a Retrospective Study.
|
||
Completed |
NCT03753893 -
Ocular Manifestations in Rheumatic Diseases
|
||
Recruiting |
NCT04855045 -
An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.
|
Phase 2/Phase 3 |